Team

While the Relay Therapeutics team brings a wealth of different experiences to the table, we are united in our mission to bring protein motion to the center of drug discovery. Our roles don’t dictate our daily activities – every employee is empowered to make an impact, seize opportunity and to develop skills and expertise.

Shuffle for more employee spotlights

THE RELAY TEAM

  • André Lescarbeau

    André Lescarbeau
    Medicinal Chemistry

    André Lescarbeau

    Caught in a sandstorm in the Thar desert (border of India and Pakistan) André was forced to spend the night sleeping between 2 camels to avoid being buried alive.

  • Chris Owen

    Chris Owen
    Biology

    Chris Owen

    Chris has been a practitioner of martial arts (Kung Fu and Jiu Jitsu) for twenty years. 

  • Alex Taylor, Ph.D.

    Alex Taylor, Ph.D.
    Medicinal Chemistry

    Alex Taylor, Ph.D.

    During summers in high school, Alex worked in a factory making the partitions between the front and back seats of police cars, where he learned to operate a forklift.

  • Jessica B. Casaletto, Ph.D.

    Jessica B. Casaletto, Ph.D.
    Biology

    Jessica B. Casaletto, Ph.D.

    Jessica became a “Cameron Crazie” while in grad school at Duke, attending every home basketball game for 4 consecutive seasons (several of them with her face painted Duke blue!).

  • Roberto Valverde, Ph.D.

    Roberto Valverde, Ph.D.
    Structural Biology

    Roberto Valverde, Ph.D.

    Roberto once spent a week in Eastern Ukraine in hiding from ex-KGB officials.

  • Barry Toure, Ph.D.

    Barry Toure, Ph.D.
    Medicinal Chemistry

    Barry Toure, Ph.D.

    Barry hasn’t watched a baseball game since 1994 – the year his hometown Montreal Expos’ shot at a World Series championship was denied due to the baseball strike.

  • Jeremy Wilbur, Ph.D.

    Jeremy Wilbur, Ph.D.
    Structural Biology

    Jeremy Wilbur, Ph.D.

    Jeremy once successfully battled a ring-tailed cat interested in snagging his food while on the side of a 1,000ft cliff in the middle of the night.

  • Bret Williams, Ph.D.

    Bret Williams, Ph.D.
    Biology

    Bret Williams, Ph.D.

    Bret played basketball on one of the only carpeted high school gym floors in the United States.

  • Matt Zubrowski

    Matt Zubrowski
    Biology

    Matt Zubrowski

    Matt completed his first Ironman triathlon in 2015. He finished the year as Bronze Ironman All World Athlete, ranking him among the top 10% for his age group globally.

  • Levi Pierce, Ph.D.

    Levi Pierce, Ph.D.
    Computation & Informatics

    Levi Pierce, Ph.D.

    In high school Levi launched countless flaming soccer balls from a 50′ trebuchet siege engine he constructed in his backyard.

  • Jim Watters, Ph.D.

    Jim Watters, Ph.D.
    Biology

    Jim Watters, Ph.D.

    Jim is an avid basketball player (currently recruiting for Relay’s basketball team) and a registered US patent agent in his spare time.

  • Ted Peters

    Ted Peters
    Compound Management

    Ted Peters

    Ted has kept ticket stubs from every event he’s ever attended. 

  • Sanjiv K. Patel, M.A., M.D., MBA

    Sanjiv K. Patel, M.A., M.D., MBA
    President & Chief Executive Officer

    Sanjiv K. Patel, M.A., M.D., MBA

    Sanjiv confesses that he is a terrible driver, having failed driving tests in at least two countries.

  • Christine Cutting

    Christine Cutting
    Operations & Administration

    Christine Cutting

    Christine has studied, volunteered and worked around the globe in such locations as Guatemala, Spain, Ecuador, Central Pennsylvania and Liberia collecting artwork and recipes as she goes.

  • Yong Tang, Ph.D.

    Yong Tang, Ph.D.
    Structural Biology

    Yong Tang, Ph.D.

    Yong owns a canoe that has trekked the Brandywine and Charles Rivers and has provided many mock runs for his kids and friends in the backyard.

  • Christian Klammt, Ph.D.

    Christian Klammt, Ph.D.
    Biophysics

    Christian Klammt, Ph.D.

    Since relocating from San Diego, Christian has lived by the motto ‘there’s no wrong weather, just wrong clothing.’ He continues to surf and mountain bike all year long.

  • Dipali Patel, Ph.D.

    Dipali Patel, Ph.D.
    Structural Biology

    Dipali Patel, Ph.D.

    Dipali believes there’s nothing a cup of English breakfast tea (like how the Brits make) and a fabulous blow-dry can’t fix!

  • Randy Kipp, Ph.D.

    Randy Kipp, Ph.D.
    Biochemistry

    Randy Kipp, Ph.D.

    Randy can recite Les Miserables in its entirety.

  • Lina Gu, Ph.D.

    Lina Gu, Ph.D.
    Biochemistry

    Lina Gu, Ph.D.

    Lina once used a mid-winter work sabattical to work out in the mornings and eat in the afternoons.

  • Ken Mullen

    Ken Mullen
    Operations

    Ken Mullen

    Ken was a state champion speaker and debater. He still likes to talk and argue.

  • Pascal Fortin, Ph.D.

    Pascal Fortin, Ph.D.
    Biochemistry Biophysics & Structural Biology

    Pascal Fortin, Ph.D.

    An avid rock climber, Pascal took a three-month detour around the earth to climb some of the planet’s best cliffs on his way to Boston to start his postdoctoral studies.

  • Pat Walters, Ph.D.

    Pat Walters, Ph.D.
    Computational Chemistry

    Pat Walters, Ph.D.

    Pat played bass in The Colours (1980s), The Ironworkers (1990s) and One Monkey Away (2000s).

  • Christine Bellon, Ph.D., J.D.

    Christine Bellon, Ph.D., J.D.
    Legal Affairs

    Christine Bellon, Ph.D., J.D.

    Chris originally wanted to be an archeologist and worked at a dig site focused on the burial mounds in Kampsville, Illinois. After spending a week digging in 100+ degree weather, she reconsidered her career choice.

  • Kelley Shortsleeves

    Kelley Shortsleeves
    Medicinal Chemistry

    Kelley Shortsleeves

    Kelley spent her senior year of college trying to find the perfect chocolate chip cookie recipe. She can now bake them from memory.

  • Jon Weiss

    Jon Weiss
    Computation & Informatics

    Jon Weiss

    Jon earned the nickname “MacGyver”  in college when he successfully opened a wine bottle with a bobby pin.

  • Lucian DiPietro, Ph.D.

    Lucian DiPietro, Ph.D.
    Medicinal Chemistry

    Lucian DiPietro, Ph.D.

    Lucian once incurred a foosball injury requiring game stoppage and has a lifetime undefeated record as anchor for tug of war teams.

  • Mark Murcko, Ph.D.

    Mark Murcko, Ph.D.
    Chief Scientific Officer

    Mark Murcko, Ph.D.

    In college, Mark once played the arcade game “Battlezone” for 3.5 hours on a single quarter and won enough bar bets to last an entire semester.

  • Elizabeth Kelley, Ph.D.

    Elizabeth Kelley, Ph.D.
    Medicinal Chemistry

    Elizabeth Kelley, Ph.D.

    As a child, Beth won first place for her self-made Energizer Bunny Halloween costume. Other self-made favorites included: grapes and a sandwich.

  • Jackie Spitler

    Jackie Spitler
    Administration

    Jackie Spitler

    While nannying in New Zealand Jackie became an adoptive mother to a lamb.

  • Erin Brophy

    Erin Brophy
    Biochemistry & Biophysics

    Erin Brophy

    For several months, Erin worked in Dorsoduro, Venice surveying outdoor art and sculpture developing an algorithm to determine the city’s priority for preservation efforts.

  • Heike Schoenherr, Ph.D.

    Heike Schoenherr, Ph.D.
    Medicinal Chemistry

    Heike Schoenherr, Ph.D.

    Heike spent twenty years on stage as a semi-professional dancer. These days, she’s more likely to be found in the lab.

  • Deborah Palestrant, Ph.D., MBA

    Deborah Palestrant, Ph.D., MBA
    Corporate Development and Strategy

    Deborah Palestrant, Ph.D., MBA

    While completing her Ph.D. and postdoc work, Deb earned a black belt in karate.

  • Christine Bellon, Ph.D., J.D.

    Senior Vice President, Legal Affairs

    Christine Bellon brings to Relay more than 20 years of legal, intellectual property and management experience in the biopharmaceutical industry. Prior to Relay, she served as Vice President of Legal Affairs and Corporate Secretary at Blueprint Medicines. As one of Blueprint’s early employees, she played key roles in building Blueprint’s global IP portfolio, securing strategic partnerships in rare genetic diseases and cancer immunotherapy and in Blueprint’s initial public offering. Prior to Blueprint, she served in legal leadership roles at Hydra Biosciences and Infinity Pharmaceuticals. Earlier in her career, she practiced law in the Boston office of Fish & Richardson P.C. Chris is the Chair of the Overseers and a Trustee of the Boston Museum of Science.

    Chris holds a B.S. in Chemistry from Yale University; a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology, where she did research in the laboratory of K. Barry Sharpless; and a J.D. from Columbia Law School.

    Fun Fact:

    Chris originally wanted to be an archeologist and worked at a dig site focused on the burial mounds in Kampsville, Illinois. After spending a week digging in 100+ degree weather, she reconsidered her career choice.

  • Mark Murcko, Ph.D.

    Chief Scientific Officer

    Mark Murcko, Ph.D. has directly contributed to seven marketed drugs and several others currently in mid-stage clinical trials.

    Until November 2011, Mark was chief technology officer and chair of the scientific advisory board of Vertex Pharmaceuticals. In this role, he was responsible for the identification, validation and incorporation of disruptive technologies across global R&D. Mark is a co-inventor of the HCV protease inhibitor Incivek (telaprevir), as well as Agenerase (amprenavir) and Lexiva (fosamprenavir), Vertex’s two marketed drugs for the treatment of HIV. In addition, he guided the early efforts of the Vertex’s cystic fibrosis program that later produced the marketed drugs Kalydeco (ivacaftor) and Orkambi (lumacaftor / ivacaftor). He is also a co-inventor of eight other clinical candidates in the areas of cancer, inflammation/immunology and infectious disease, and was responsible for starting many of Vertex’s programs in these and other disease areas, notably leading to Vertex’s influenza drug VX-787 and cancer drug VX-970, both currently in mid-stage clinical trials.

    Prior to Vertex, Mark worked at Merck Sharpe & Dohme, where he helped discover clinical candidates against infection and cardiovascular and ocular diseases, including inhibitors of the enzyme carbonic anhydrase for the treatment of glaucoma. One of Merck’s development candidates in this area, dorzolamide, was commercialized in two products, Trusopt and the combination medicine Cosopt (dorzolamide/ timolol).  Trusopt was the first marketed drug in pharmaceutical history to result from a structure-based drug design program.

    Mark is a senior lecturer in the Department of Biological Engineering at MIT.  In addition, Mark is a member of numerous scientific advisory boards and corporate boards of directors for a diverse range of organizations.  He served as the chair of the 2013 Gordon Research Conference in Medicinal Chemistry and is currently a member of the Board of Trustees of the GRC.  He is a co-inventor on more than 50 issued and pending patents and has co-authored more than 85 scientific articles.  Mark holds a Ph.D. in organic chemistry from Yale University and a B.S., summa cum laude, in chemistry and applied mathematics from Fairfield University.

    Fun Fact:

    In college, Mark once played the arcade game “Battlezone” for 3.5 hours on a single quarter and won enough bar bets to last an entire semester.

  • Sanjiv K. Patel, M.A., M.D., MBA

    President & Chief Executive Officer

    Dr. Sanjiv Patel brings to Relay over 20 years of life sciences industry experience. Prior to Relay, Sanjiv was at Allergan for over 10 years, and played a key part in Allergan’s sustained growth and value creation over that period. Sanjiv held roles of increased responsibility, including leading Global Strategic Marketing for all franchises and general management of Allergan’s fastest growth geographic region, the Emerging Markets.

    He was most recently part of Allergan’s Executive Team, as Chief Strategy Officer and at the center of some of the industry’s largest transactions. His work with the Senior Leadership Team of Allergan defined its long-term objectives and strategy, including divestment and integration planning activities.

    Prior to Allergan, Sanjiv was a Management Consultant at Boston Consulting Group in London and he started his career as a surgeon in the U.K.’s National Health Service. Sanjiv received his M.B.A. from INSEAD, MBBS from the University of London and has a M.A. in Neurosciences from Cambridge University.

    Fun Fact:

    Sanjiv confesses that he is a terrible driver, having failed driving tests in at least two countries.

  • Alexis Borisy

    Executive Chairman

    Alexis Borisy is a partner at Third Rock Ventures and chairman of Relay Therapeutics’ board of directors. He is a successful biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Alexis joined Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies. He has played key roles in launching and building several of Third Rock’s portfolio companies. He was the chairman of the board, co-founder, and interim CEO of Foundation Medicine, interim CEO of Warp Drive and Blueprint Medicines, and currently serves as a board member of Foundation Medicine, Warp Drive Bio, Blueprint Medicines, Editas Medicine, Tango Therapeutics, and Revolution Medicine.

    Prior to joining Third Rock Ventures, Alexis founded CombinatoRx in 2000, serving as its chief executive officer and bringing the company public on the NASDAQ. He has raised billions in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Alexis was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar.

    Alexis’ undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Alexis is a trustee of the Boston Museum of Science, is a co-founder and former chairman of FORMA Therapeutics, and serves on the board of the National Venture Capital Association.

    Fun Fact:

    Alexis’ first job was selling peanuts at Wisconsin Badger football games at age 14.

  • Mark Murcko, Ph.D.

    Mark Murcko, Ph.D. has directly contributed to seven marketed drugs and several others currently in mid-stage clinical trials.

    Until November 2011, Mark was chief technology officer and chair of the scientific advisory board of Vertex Pharmaceuticals. In this role, he was responsible for the identification, validation and incorporation of disruptive technologies across global R&D. Mark is a co-inventor of the HCV protease inhibitor Incivek (telaprevir), as well as Agenerase (amprenavir) and Lexiva (fosamprenavir), Vertex’s two marketed drugs for the treatment of HIV. In addition, he guided the early efforts of the Vertex’s cystic fibrosis program that later produced the marketed drugs Kalydeco (ivacaftor) and Orkambi (lumacaftor / ivacaftor). He is also a co-inventor of eight other clinical candidates in the areas of cancer, inflammation/immunology and infectious disease, and was responsible for starting many of Vertex’s programs in these and other disease areas, notably leading to Vertex’s influenza drug VX-787 and cancer drug VX-970, both currently in mid-stage clinical trials.

    Prior to Vertex, Mark worked at Merck Sharpe & Dohme, where he helped discover clinical candidates against infection and cardiovascular and ocular diseases, including inhibitors of the enzyme carbonic anhydrase for the treatment of glaucoma. One of Merck’s development candidates in this area, dorzolamide, was commercialized in two products, Trusopt and the combination medicine Cosopt (dorzolamide/ timolol).  Trusopt was the first marketed drug in pharmaceutical history to result from a structure-based drug design program.

    Mark is a senior lecturer in the Department of Biological Engineering at MIT.  In addition, Mark is a member of numerous scientific advisory boards and corporate boards of directors for a diverse range of organizations.  He served as the chair of the 2013 Gordon Research Conference in Medicinal Chemistry and is currently a member of the Board of Trustees of the GRC.  He is a co-inventor on more than 50 issued and pending patents and has co-authored more than 85 scientific articles.  Mark holds a Ph.D. in organic chemistry from Yale University and a B.S., summa cum laude, in chemistry and applied mathematics from Fairfield University.

    Fun Fact:

    In college, Mark once played the arcade game “Battlezone” for 3.5 hours on a single quarter and won enough bar bets to last an entire semester.

  • Sanjiv K. Patel, M.A., M.D., M.B.A.

    Dr. Sanjiv Patel brings to Relay over 20 years of life sciences industry experience. Prior to Relay, Sanjiv was at Allergan for over 10 years, and played a key part in Allergan’s sustained growth and value creation over that period. Sanjiv held roles of increased responsibility, including leading Global Strategic Marketing for all franchises and general management of Allergan’s fastest growth geographic region, the Emerging Markets.

    He was most recently part of Allergan’s Executive Team, as Chief Strategy Officer and at the center of some of the industry’s largest transactions. His work with the Senior Leadership Team of Allergan defined its long-term objectives and strategy, including divestment and integration planning activities.

    Prior to Allergan, Sanjiv was a Management Consultant at Boston Consulting Group in London and he started his career as a surgeon in the U.K.’s National Health Service. Sanjiv received his M.B.A. from INSEAD, MBBS from the University of London and has a M.A. in Neurosciences from Cambridge University.

    Fun Fact:

    Sanjiv confesses that he is a terrible driver, having failed driving tests in at least two countries.

  • Laura Shawver, Ph.D.

    Laura Shawver sees cancer from the perspective of scientist, survivor and CEO. She is an experienced Biotech executive with more than 25 years of experience in the development of small molecule drugs for cancer and other serious diseases. Since 2011, Laura has been CEO and Director of Cleave Biosciences which is focused on developing novel cancer agents for difficult to treat cancers. Prior to Cleave she was Entrepreneur in Residence for 5AM Ventures and from 2002 – 2010, Laura was the CEO and Director of Phenomix Corporation. Previously, Laura was the President of SUGEN, Inc. from 2000 – 2002 after holding various positions since 1992. Following her own diagnosis and treatment for ovarian cancer in 2006, she founded the non-profit organization, The Clearity Foundation, to help other women battling the disease access molecular profiling and improve treatment options. Laura has also served on the Scientific Advisory Committee for Stand Up To Cancer since 2008 and serves on the Scientific Advisory Board for Ideaya Biosciences. Laura received her Ph.D. in Pharmacology and a B.S. degree in Microbiology, both from the University of Iowa.

    Fun Fact:

    Laura has loved science from an early age and came very close to blowing up her high school chemistry lab. Thankfully, it was rescued by the fire department.  When not engaged in an experiment, Laura surfs at various southern California beaches.

  • Markus Warmuth, M.D.

    Dr. Markus Warmuth currently serves as President and Chief Executive Officer of H3 Biomedicine and is responsible for the overall scientific and business direction of the company. Markus joined H3 shortly after inception and has since built it into a clinical stage biotech company, pursuing data science driven drug discovery.

    Prior to joining H3 in 2011, Markus was Head of Oncology Drug Discovery for the Novartis Institute for Biomedical Research (NIBR), Cambridge (U.S.) Site where he led a significant portion of NIBR’s global oncology drug discovery portfolio. From 2002 to April 2008, he served as Director of Kinase Biology, Head of the Oncology Pharmacology Program and as a member of the Research and Drug Discovery Steering Committee for the Genomics Institute of the Novartis Research Foundation (GNF), San Diego. While at GNF and NIBR he lead groups involved in now approved drugs such as Ceritinib and Ribociclib.

    Markus received his doctorate in medicine from the Ludwig-Maximilians-University of Munich, Germany, where he trained in Internal medicine and oncology.

    Markus has served on the SAB of Keystone Symposia and currently serves on the SRB of the Starr Cancer Consortium.

    Fun Fact:

    When Markus was 28 years old he was involved in starting up a company in Germany. To appear more senior to investors he decided to dye his hair grey. Unfortunately, they came out purple, which didn’t help his credibility with investors. However, a few days later he got to know his wife, Cindy.